Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming SITC Annual Meeting
Krakow, Poland – November 9, 2021 – Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology announced today that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC.
Ryvu will present a poster on novel, orally administered HPK1 inhibitors which exhibit nanomolar activity in an immunosuppressive environment. These small molecules have shown favorable PK profiles allowing for in vivo target engagement after oral administration, and hold promising potential as a treatment in a variety of solid tumor indications.
The second poster will highlight a novel small-molecule STING agonist, RVU-27065. Selective STING pathway activation with RVU-27065 allows for repolarization of immunosuppressive tumor-associated macrophages into a pro-inflammatory phenotype without a negative impact on T-cell function. With favorable drug-like properties and a good safety profile, RVU-27065 is a promising candidate for standalone treatment as well as targeted delivery as a payload for antibodies.
Poster Presentations:
- Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response
- Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration